Newly Formed Abivax Of France Links With Cuba To Develop Vaccines
This article was originally published in The Pink Sheet Daily
New French biotech Abivax is tapping into Cuba’s vaccine expertise in hopes of becoming a leader in the field, initially targeting Asia with its lead Hepatitis B jab, which it says offers the potential to cure the disease.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.